Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nabih Maslah

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Leukemia|March 31, 2023
Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscapeNabih Maslah, Lina Benajiba, Stephane Giraudier, et al.
British Journal of Haematology|June 19, 2021
In vitro assessment of the sensitivity to APR-246 + azacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patientsNabih Maslah, Yantcha Diawara, Marie Sebert, et al.
Haematologica|May 17, 2020
CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patientsBruno Cassinat, Emmanuelle Verger, Nabih Maslah, et al.
International Journal of Laboratory Hematology|July 3, 2020
Pitfalls in CALR exon 9 mutation detection: A single-center experience in 571 positive patientsEmmanuelle Verger, Nabih Maslah, Marie-Helene Schlageter, et al.
Blood Advances|January 14, 2022
Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibitionNabih Maslah, Emmanuelle Verger, Stéphane Giraudier, et al.
Leukemia|May 22, 2024
Niclosamide combined to Azacitidine to target TP53-mutated MDS/AML cellsNabih Maslah, Salome Rety, Melina Bonnamy, et al.
Annals of Hematology|September 28, 2018
Next-generation sequencing for JAK2 mutation testing: advantages and pitfallsNabih Maslah, Emmanuelle Verger, Marie-Helene Schlageter, et al.
British Journal of Haematology|December 22, 2022
Reduced murine double minute 2 and 4 protein, but not messenger RNA, expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemiaNorman Salomao, Nabih Maslah, Anouk Giulianelli, et al.
Haematologica|August 16, 2019
Masked polycythemia vera: analysis of a single center cohort of 2480 red cell massesNabih Maslah, Juliette Soret, Christine Dosquet, et al.
British Journal of Haematology|September 25, 2021
Revisiting Diagnostic performances of serum erythropoïetin level and JAK2 mutation for polycythemias: analysis of a cohort of 1090 patients with red cell mass measurementNabih Maslah, Odonchimeg Ravdan, Louis Drevon, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Leukemia|March 31, 2023
Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscapeNabih Maslah, Lina Benajiba, Stephane Giraudier, et al.
British Journal of Haematology|June 19, 2021
In vitro assessment of the sensitivity to APR-246 + azacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patientsNabih Maslah, Yantcha Diawara, Marie Sebert, et al.
Haematologica|May 17, 2020
CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patientsBruno Cassinat, Emmanuelle Verger, Nabih Maslah, et al.
International Journal of Laboratory Hematology|July 3, 2020
Pitfalls in CALR exon 9 mutation detection: A single-center experience in 571 positive patientsEmmanuelle Verger, Nabih Maslah, Marie-Helene Schlageter, et al.
Blood Advances|January 14, 2022
Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibitionNabih Maslah, Emmanuelle Verger, Stéphane Giraudier, et al.
Leukemia|May 22, 2024
Niclosamide combined to Azacitidine to target TP53-mutated MDS/AML cellsNabih Maslah, Salome Rety, Melina Bonnamy, et al.
Annals of Hematology|September 28, 2018
Next-generation sequencing for JAK2 mutation testing: advantages and pitfallsNabih Maslah, Emmanuelle Verger, Marie-Helene Schlageter, et al.
British Journal of Haematology|December 22, 2022
Reduced murine double minute 2 and 4 protein, but not messenger RNA, expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemiaNorman Salomao, Nabih Maslah, Anouk Giulianelli, et al.
Haematologica|August 16, 2019
Masked polycythemia vera: analysis of a single center cohort of 2480 red cell massesNabih Maslah, Juliette Soret, Christine Dosquet, et al.
British Journal of Haematology|September 25, 2021
Revisiting Diagnostic performances of serum erythropoïetin level and JAK2 mutation for polycythemias: analysis of a cohort of 1090 patients with red cell mass measurementNabih Maslah, Odonchimeg Ravdan, Louis Drevon, et al.
Pageof 3